Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ICCM NASDAQ:NXL NASDAQ:SINT NASDAQ:VBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICCMIceCure Medical$2.49+4.3%$7.53$2.38▼$42.00$7.00M0.429,970 shs15,730 shsNXLNexalin Technology$0.42-3.5%$0.42$0.31▼$2.00$8.56M3.8616,198 shs80,644 shsSINTSintx Technologies$2.18+2.6%$2.39$1.86▼$6.78$9.40M0.6641,764 shs2,312 shsVBIOValion Bio, Inc. Common Stock$0.55-2.1%$0.95$0.52▼$5.60$1.77M1.79273,645 shs33,984 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICCMIceCure Medical0.00%-45.18%-65.33%-89.09%-91.80%NXLNexalin Technology0.00%-17.70%+25.84%+5.97%-62.52%SINTSintx Technologies0.00%+4.43%-6.61%-24.29%-35.17%VBIOValion Bio, Inc. Common Stock0.00%-25.53%-35.68%-43.40%-84.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICCMIceCure Medical$2.49+4.3%$7.53$2.38▼$42.00$7.00M0.429,970 shs15,730 shsNXLNexalin Technology$0.42-3.5%$0.42$0.31▼$2.00$8.56M3.8616,198 shs80,644 shsSINTSintx Technologies$2.18+2.6%$2.39$1.86▼$6.78$9.40M0.6641,764 shs2,312 shsVBIOValion Bio, Inc. Common Stock$0.55-2.1%$0.95$0.52▼$5.60$1.77M1.79273,645 shs33,984 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICCMIceCure Medical0.00%-45.18%-65.33%-89.09%-91.80%NXLNexalin Technology0.00%-17.70%+25.84%+5.97%-62.52%SINTSintx Technologies0.00%+4.43%-6.61%-24.29%-35.17%VBIOValion Bio, Inc. Common Stock0.00%-25.53%-35.68%-43.40%-84.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICCMIceCure Medical 2.40Hold$62.702,415.04% UpsideNXLNexalin Technology 1.00SellN/AN/ASINTSintx Technologies 2.50Moderate Buy$9.33329.12% UpsideVBIOValion Bio, Inc. Common Stock 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest VBIO, SINT, NXL, and ICCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026SINTSintx Technologies Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.005/20/2026SINTSintx Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/14/2026ICCMIceCure Medical Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$90.00 ➝ $30.005/4/2026ICCMIceCure Medical Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/21/2026ICCMIceCure Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SINTSintx Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026VBIOValion Bio, Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026SINTSintx Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.004/8/2026SINTSintx Technologies Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $12.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICCMIceCure Medical$3.57M1.96N/AN/A$3.72 per share0.67NXLNexalin Technology$275.58K31.07N/AN/A$0.20 per share2.08SINTSintx Technologies$1.02M9.21N/AN/A$0.80 per share2.72VBIOValion Bio, Inc. Common StockN/AN/AN/AN/A$6.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICCMIceCure Medical-$15.06M-$7.21N/AN/AN/A-441.60%-211.73%-119.13%8/12/2026 (Estimated)NXLNexalin Technology-$8.22M-$0.47N/AN/AN/A-3,018.12%-191.88%-166.43%9/2/2026 (Estimated)SINTSintx Technologies-$10.36M-$5.07N/AN/AN/A-1,058.60%-366.49%-115.04%8/13/2026 (Estimated)VBIOValion Bio, Inc. Common Stock-$8.88M-$6.68N/AN/AN/AN/A-138.10%-63.67%N/ALatest VBIO, SINT, NXL, and ICCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026SINTSintx Technologies-$0.66-$0.70-$0.04-$0.70$0.30 million$0.38 million5/14/2026Q1 2026VBIOValion Bio, Inc. Common StockN/A-$2.23N/A-$2.23N/AN/A5/12/2026Q1 2026ICCMIceCure Medical-$0.03-$0.06-$0.03$1.80$1.34 million$0.91 million5/8/2026Q1 2026NXLNexalin Technology-$0.10-$0.11-$0.01-$0.11$0.02 million$0.01 million3/30/2026Q4 2025VBIOValion Bio, Inc. Common Stock-$408.00-$1.0310+$406.9690-$1.35$0.46 millionN/A3/25/2026Q4 2025NXLNexalin Technology-$0.12-$0.13-$0.01-$0.13$0.08 million$0.17 million3/17/2026Q4 2025ICCMIceCure Medical-$1.20-$1.80-$0.60-$0.0620$1.30 million$1.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthICCMIceCure MedicalN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/AVBIOValion Bio, Inc. Common StockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICCMIceCure MedicalN/A2.521.97NXLNexalin TechnologyN/A4.073.85SINTSintx TechnologiesN/A1.040.70VBIOValion Bio, Inc. Common Stock0.623.313.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICCMIceCure Medical0.62%NXLNexalin Technology0.65%SINTSintx Technologies18.38%VBIOValion Bio, Inc. Common Stock4.25%Insider OwnershipCompanyInsider OwnershipICCMIceCure Medical2.44%NXLNexalin Technology25.26%SINTSintx Technologies4.08%VBIOValion Bio, Inc. Common Stock14.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableICCMIceCure Medical602.81 million2.74 millionNot OptionableNXLNexalin Technology320.58 million15.38 millionNot OptionableSINTSintx Technologies404.32 million4.14 millionNot OptionableVBIOValion Bio, Inc. Common Stock103.20 million3.13 millionNot OptionableVBIO, SINT, NXL, and ICCM HeadlinesRecent News About These CompaniesVALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROMEMay 19, 2026 | prnewswire.comValion Bio, Inc.: Valion Bio Reports First Quarter 2026 Financial ResultsMay 15, 2026 | finanznachrichten.deValion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling workMay 14, 2026 | seekingalpha.comValion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks TranscriptMay 14, 2026 | seekingalpha.comValion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ PlatformMay 14, 2026 | prnewswire.comVALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTSMay 14, 2026 | prnewswire.comValion Bio to Report First Quarter 2026 Financial Results on May 14, 2026May 11, 2026 | prnewswire.comValion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™May 6, 2026 | prnewswire.comVALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSIONMay 5, 2026 | prnewswire.comTivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple ...April 23, 2026 | finance.yahoo.comTivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream ModelApril 23, 2026 | prnewswire.comSheryle Bolton Purchases 10,000 Shares of Tivic Health Systems (NASDAQ:TIVC) StockApril 21, 2026 | insidertrades.comTivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7thApril 15, 2026 | prnewswire.comTivic Health Systems, Inc.April 3, 2026 | edition.cnn.comTivic Health Systems (NASDAQ:TIVC) Director Christina Rizopoulos Valauri Acquires 19,000 SharesApril 3, 2026 | insidertrades.comTivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of EntolimodMarch 31, 2026 | accessnewswire.comAHead to Head Analysis: Tivic Health Systems (NASDAQ:TIVC) versus American Well (NYSE:AMWL)March 29, 2026 | defenseworld.netDTivic Health Systems: Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual ConferenceMarch 27, 2026 | finanznachrichten.deTivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual ConferenceMarch 27, 2026 | accessnewswire.comATivic Health Systems: Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation SyndromeMarch 26, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVBIO, SINT, NXL, and ICCM Company DescriptionsIceCure Medical NASDAQ:ICCM$2.49 +0.10 (+4.31%) As of 09:52 AM Eastern This is a fair market value price provided by Massive. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Nexalin Technology NASDAQ:NXL$0.42 -0.02 (-3.48%) As of 09:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.Sintx Technologies NASDAQ:SINT$2.17 +0.06 (+2.59%) As of 09:49 AM Eastern This is a fair market value price provided by Massive. Learn more.Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.Valion Bio, Inc. Common Stock NASDAQ:VBIO$0.55 -0.01 (-2.08%) As of 09:39 AM EasternTivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
